- Home
- IOBT vs CASI Comparison
IOBT vs CASI Comparison
Compare IOBT & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOBT
- CASI
- Stock Information
- Founded
- IOBT 2014
- CASI 1991
- Country
- IOBT Denmark
- CASI China
- Employees
- IOBT N/A
- CASI N/A
- Industry
- IOBT Biotechnology: Pharmaceutical Preparations
- CASI Biotechnology: Pharmaceutical Preparations
- Sector
- IOBT Health Care
- CASI Health Care
- Exchange
- IOBT Nasdaq
- CASI Nasdaq
- Market Cap
- IOBT 56.7M
- CASI 58.8M
- IPO Year
- IOBT 2021
- CASI 1996
- Fundamental
- Price
- IOBT $0.84
- CASI $2.62
- Analyst Decision
- IOBT Strong Buy
- CASI Strong Buy
- Analyst Count
- IOBT 3
- CASI 1
- Target Price
- IOBT $9.33
- CASI $6.00
- AVG Volume (30 Days)
- IOBT 203.5K
- CASI 42.2K
- Earning Date
- IOBT 03-04-2025
- CASI 11-15-2024
- Dividend Yield
- IOBT N/A
- CASI N/A
- EPS Growth
- IOBT N/A
- CASI N/A
- EPS
- IOBT N/A
- CASI N/A
- Revenue
- IOBT N/A
- CASI $22,055,000.00
- Revenue This Year
- IOBT N/A
- CASI N/A
- Revenue Next Year
- IOBT N/A
- CASI $134.79
- P/E Ratio
- IOBT N/A
- CASI N/A
- Revenue Growth
- IOBT N/A
- CASI N/A
- 52 Week Low
- IOBT $0.66
- CASI $2.05
- 52 Week High
- IOBT $1.89
- CASI $8.19
- Technical
- Relative Strength Index (RSI)
- IOBT 45.71
- CASI 38.56
- Support Level
- IOBT $0.77
- CASI $2.44
- Resistance Level
- IOBT $0.95
- CASI $2.76
- Average True Range (ATR)
- IOBT 0.08
- CASI 0.29
- MACD
- IOBT -0.01
- CASI 0.03
- Stochastic Oscillator
- IOBT 22.16
- CASI 21.18
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.